Avalo Therapeutics (AVTX) Competitors $4.85 +0.10 (+2.11%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$4.92 +0.07 (+1.44%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX vs. SOPH, MNPR, SCPH, DSGN, VOR, ACIU, ESPR, PROK, KOD, and SLSShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include SOPHiA GENETICS (SOPH), Monopar Therapeutics (MNPR), scPharmaceuticals (SCPH), Design Therapeutics (DSGN), Vor Biopharma (VOR), AC Immune (ACIU), Esperion Therapeutics (ESPR), ProKidney (PROK), Kodiak Sciences (KOD), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Its Competitors SOPHiA GENETICS Monopar Therapeutics scPharmaceuticals Design Therapeutics Vor Biopharma AC Immune Esperion Therapeutics ProKidney Kodiak Sciences SELLAS Life Sciences Group Avalo Therapeutics (NASDAQ:AVTX) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment. Do analysts recommend AVTX or SOPH? Avalo Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 518.56%. SOPHiA GENETICS has a consensus price target of $7.00, suggesting a potential upside of 96.63%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Avalo Therapeutics is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders & institutionals have more ownership in AVTX or SOPH? 87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 0.3% of Avalo Therapeutics shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, AVTX or SOPH? Avalo Therapeutics has higher earnings, but lower revenue than SOPHiA GENETICS. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$440K119.38-$35.13MN/AN/ASOPHiA GENETICS$65.17M3.64-$62.49M-$1.00-3.56 Does the media refer more to AVTX or SOPH? In the previous week, Avalo Therapeutics had 2 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 3 mentions for Avalo Therapeutics and 1 mentions for SOPHiA GENETICS. Avalo Therapeutics' average media sentiment score of 0.34 beat SOPHiA GENETICS's score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SOPHiA GENETICS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, AVTX or SOPH? Avalo Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500. Is AVTX or SOPH more profitable? Avalo Therapeutics has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -98.51%. Avalo Therapeutics' return on equity of 111.00% beat SOPHiA GENETICS's return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A 111.00% 58.88% SOPHiA GENETICS -98.51%-63.47%-40.06% SummaryAvalo Therapeutics beats SOPHiA GENETICS on 11 of the 14 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.43M$2.68B$5.50B$8.95BDividend YieldN/A1.79%5.25%4.04%P/E RatioN/A8.9826.9720.11Price / Sales119.38714.59425.92119.81Price / CashN/A159.8036.8257.86Price / Book0.384.517.985.56Net Income-$35.13M$31.26M$3.16B$248.40M7 Day Performance-1.82%3.57%2.36%4.67%1 Month Performance6.36%1.28%2.15%6.64%1 Year Performance-62.29%1.08%33.78%21.31% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics2.9977 of 5 stars$4.85+2.1%$30.00+518.6%-63.1%$51.43M$440K0.0040SOPHSOPHiA GENETICS2.3499 of 5 stars$3.10+0.3%$7.00+125.8%-21.2%$206.06M$65.17M-3.10520News CoveragePositive NewsMNPRMonopar Therapeutics2.8969 of 5 stars$35.78+6.5%$56.50+57.9%+940.0%$205.47MN/A-10.2810News CoverageAnalyst ForecastGap UpSCPHscPharmaceuticals4.1364 of 5 stars$3.81-1.6%$14.00+267.5%-9.4%$204.30M$36.33M-1.9930DSGNDesign Therapeutics0.3745 of 5 stars$3.37-5.6%$4.00+18.7%+4.0%$202.66MN/A-3.4040Positive NewsVORVor Biopharma3.9425 of 5 stars$1.62+52.8%$5.63+247.4%+164.9%$202.44MN/A-0.98140Options VolumeGap UpHigh Trading VolumeACIUAC Immune2.7562 of 5 stars$2.03+1.0%$12.00+491.1%-40.5%$201.82M$31.02M-3.50140ESPREsperion Therapeutics4.2296 of 5 stars$0.98-0.9%$7.00+611.1%-51.3%$196.93M$332.31M-1.23200Positive NewsPROKProKidney0.7464 of 5 stars$0.59-11.5%$3.50+491.1%+68.8%$195.73M$80K-0.993Trending NewsGap UpHigh Trading VolumeKODKodiak Sciences4.1301 of 5 stars$3.73+0.8%$9.00+141.3%+58.5%$195.23MN/A-1.0390News CoverageSLSSELLAS Life Sciences Group0.1249 of 5 stars$2.19+12.3%N/A+77.9%$194.57M$1M-5.7610High Trading Volume Related Companies and Tools Related Companies SOPHiA GENETICS Competitors Monopar Therapeutics Competitors scPharmaceuticals Competitors Design Therapeutics Competitors Vor Biopharma Competitors AC Immune Competitors Esperion Therapeutics Competitors ProKidney Competitors Kodiak Sciences Competitors SELLAS Life Sciences Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
